SIROMED PHARMA, UAB Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo data| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2023 |
|---|
| 11,011,000 |
| 799,637 |
| 33,000 |
| 5,000 |
| 363 |
| 15.09 |
| 0.05 |
| 1,346,000 |
| 6,104,000 |
| 147,000 |
| 7,303,000 |
| 0.29 |
| 4.53 |
| 1.82 |
| 200,000 |
| 1.52 |
| 167,000 |
| 2024 |
|---|
| 11,422,000 |
| 875,249 |
| 167,000 |
| 126,000 |
| 9,655 |
| 15.74 |
| 1.10 |
| 1,472,000 |
| 5,429,000 |
| 252,000 |
| 6,649,000 |
| 0.29 |
| 3.69 |
| 3.29 |
| 376,000 |
| 2.99 |
| 342,000 |
| 2025 |
|---|
| 11,996,000 |
| 1,023,549 |
| 328,200 |
| 252,200 |
| 21,519 |
| 16.26 |
| 2.10 |
| 1,724,500 |
| 5,412,500 |
| 233,000 |
| 6,904,000 |
| 0.30 |
| 3.14 |
| 3.94 |
| 472,200 |
| 3.65 |
| 438,200 |
| 2025 |
|---|
| 11,996,000 |
| 1,023,549 |
| 328,200 |
| 252,200 |
| 21,519 |
| 16.26 |
| 2.10 |
| 1,724,500 |
| 5,412,500 |
| 233,000 |
| 6,904,000 |
| 0.30 |
| 3.14 |
| 3.94 |
| 472,200 |
| 3.65 |
| 438,200 |
Turnover (€)
2025
Turnover (€)
11,996,000 €5 % *
Sales per employee (€)
1,023,549 €17 % *
Profit before tax (€)
328,200 €97 % *
Net Profit (€)
252,200 €100 % *
Profit per employee (€)
21,519 €123 % *
Total profitability (%)
16.26 %3.30 % *
Net profitability (%)
2.10 %90.91 % *
Equity (€)
1,724,500 €17 % *
Amounts Payable And Liabilities (€)
5,412,500 €0 % *
Non-current Assets (€)
233,000 €-8 % *
CurrentAssets (€)
6,904,000 €4 % *
Working capital requirement
0.30 3.45 % *
Debt-to-equity ratio
3.14 -14.91 % *
EBITDA margin (%)
3.94 %19.76 % *
EBITDA (€)
472,200 €26 % *
EBIT margin (%)
3.65 %22.07 % *
EBIT (€)
438,200 €28 % *
